Pemetrexed Injection
Product Images NDC 63759-3049

16 FDA label images from Shilpa Medicare Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 63759-3049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Shilpa Medicare Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 01)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 01)
Chemical structure of Pemetrexed disodium showing its molecular composition including nitrogen, oxygen, sodium atoms and associated bonds, with a hydration state indicated as 2.5 water molecules.*
FDA Label Image

.. (28a6ab66 7974 4afa B3dc 963530d46d36 02)

.. (28a6ab66 7974 4afa B3dc 963530d46d36 02)
A Kaplan-Meier overall survival curve comparing two treatment arms over time in months. The black solid line represents the Pemetrexed plus pembrolizumab plus platinum chemotherapy group, and the gray dashed line represents Pemetrexed plus platinum chemotherapy plus placebo. The graph includes a table of the number of patients at risk at various time points for each group.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 03)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 03)
A survival curve graph comparing survival probability over time (months) for two chemotherapy regimens: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The x-axis represents survival time in months up to 30, and the y-axis shows survival probability from 0 to 1. Patient counts at risk for each treatment group are listed below the graph at various time points.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 04)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 04)
A survival probability curve comparing Pemetrexed plus Cisplatin (PC) with Gemcitabine plus Cisplatin (GC) over 30 months. The x-axis is survival time in months, and the y-axis is survival probability. A table below shows the number of patients at risk for each treatment group at various time points.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 05)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 05)
A survival probability line graph comparing Pemetrexed plus Cisplatin (PC) with Gemcitabine plus Cisplatin (GC) over a 30-month period. The x-axis represents survival time in months, and the y-axis shows survival probability. The chart includes numbers of patients at risk for each treatment regimen at different time points.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 06)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 06)
A survival probability graph comparing Pemetrexed injection versus placebo over survival time in months. The chart shows two lines, one solid for Pemetrexed and one dotted for placebo, illustrating patient survival rates over approximately 42 months. Below the chart, a table lists the number of patients at risk at various time points for both Pemetrexed and placebo groups.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 07)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 07)
A Kaplan-Meier survival curve comparing survival probability over 42 months between patients treated with Pemetrexed and those given a placebo. The graph includes a table of patients at risk at various time points for both groups, illustrating higher survival probability over time in the Pemetrexed group compared to placebo.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 08)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 08)
A Kaplan-Meier survival curve chart depicting survival probability over time in months for two groups: Pemetrexed (solid line) and Placebo (dotted line). Below the graph is a table showing the number of patients at risk at various time points for both treatment groups.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 09)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 09)
A Kaplan-Meier survival probability graph comparing Pemetrexed injection with placebo over a 36-month period. The x-axis shows survival time in months, while the y-axis represents survival probability. The chart includes lines for Pemetrexed and placebo groups with a decreasing number of patients at risk listed below the graph over time.*
FDA Label Image

Image (28a6ab66 7974 4afa B3dc 963530d46d36 10)

Image (28a6ab66 7974 4afa B3dc 963530d46d36 10)
A Kaplan-Meier survival probability curve comparing survival times in months for patients treated with Pemetrexed plus Cisplatin versus Cisplatin alone. The graph includes survival probability on the Y-axis and survival time in months on the X-axis, with patient risk numbers listed below.*
FDA Label Image

Vial Label (28a6ab66 7974 4afa B3dc 963530d46d36 11)

Vial Label (28a6ab66 7974 4afa B3dc 963530d46d36 11)
Label for Pemetrexed Injection 100 mg/10 mL (10 mg/mL) for intravenous infusion, single-dose vial, by Shilpa Medicare Limited. Contains 10 mg pemetrexed per mL in the form of pemetrexed disodium hemipentahydrate. Manufactured by Zydus Lifesciences Limited, Ahmedabad, India. Includes storage instructions, lot/expiration area, and a barcode.*
FDA Label Image

Carton Label (28a6ab66 7974 4afa B3dc 963530d46d36 12)

Carton Label (28a6ab66 7974 4afa B3dc 963530d46d36 12)
Packaging label for Pemetrexed Injection 100 mg/10 mL (10 mg/mL) sterile intravenous infusion, single dose vial. The label states it contains 10 mg pemetrexed per mL (equivalent to 12.1 mg pemetrexed disodium heptahydrate). Manufacturer listed as Zydus Lifesciences Limited, for Shilpa Medicare Limited, India. Instructions include to administer undiluted and discard unused portions.*
FDA Label Image

Vial Label (28a6ab66 7974 4afa B3dc 963530d46d36 13)

Vial Label (28a6ab66 7974 4afa B3dc 963530d46d36 13)
Label for Pemetrexed Injection 500 mg/50 mL (10 mg/mL) single dose vial for intravenous infusion. Contains 10 mg pemetrexed per mL. Manufactured by Zydus Lifesciences Limited and labeled for Shilpa Medicare Limited, India. Includes storage instructions and a barcode.*
FDA Label Image

Carton Label (28a6ab66 7974 4afa B3dc 963530d46d36 14)

Carton Label (28a6ab66 7974 4afa B3dc 963530d46d36 14)
Pemetrexed Injection 500 mg/50 mL (10 mg/mL) intravenous infusion single-dose vial packaging label. The label notes the concentration, dosing instructions to administer undiluted, and that it is a hazardous drug. It is manufactured by Zydus Lifesciences Limited and labeled for Shilpa Medicare Limited, India. Storage instructions and NDC 63759-3049-1 are included, along with a barcode and regulatory information.*
FDA Label Image

Vial Label (28a6ab66 7974 4afa B3dc 963530d46d36 15)

Vial Label (28a6ab66 7974 4afa B3dc 963530d46d36 15)
Label for Pemetrexed Injection 1000 mg/100 mL (10 mg/mL) for intravenous infusion. The label states it is a single dose vial and should be administered undiluted. It includes storage instructions and notes it is a hazardous drug. Manufactured by Zydus Lifesciences Limited for Shilpa Medicare Limited, India.*
FDA Label Image

Carton Label (28a6ab66 7974 4afa B3dc 963530d46d36 16)

Carton Label (28a6ab66 7974 4afa B3dc 963530d46d36 16)
Packaging label for Pemetrexed Injection 1000 mg/100 mL (10 mg/mL) for intravenous infusion. The label shows storage instructions (20°C to 25°C, with excursions 15°C to 30°C), manufacturer Zydus Lifesciences Limited, and labeler Shilpa Medicare Limited. It states the product is a single-dose vial, to be administered undiluted, and is classified as a hazardous drug.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.